Skip to main content

Ichthyosis

1
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Leo Pharma
Leo PharmaDenmark - Ballerup
1 program
1
TMB-001Phase 32 trials
Active Trials
NCT05295732Completed153Est. Sep 2024
NCT04154293Completed34Est. Aug 2021
Galderma
GaldermaTX - Dallas
1 program
Defining the Skin and Blood Biomarkers of IchthyosisN/A1 trial
Active Trials
NCT03417856Enrolling By Invitation200Est. Dec 2027
Vanda Pharmaceuticals
Vanda PharmaceuticalsWASHINGTON, DC
1 program
ImsidolimabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT04697056Terminated5Est. Nov 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Leo PharmaTMB-001
Vanda PharmaceuticalsImsidolimab
Leo PharmaTMB-001
GaldermaDefining the Skin and Blood Biomarkers of Ichthyosis

Clinical Trials (4)

Total enrollment: 392 patients across 4 trials

NCT05295732Leo PharmaTMB-001

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Start: Jun 2022Est. completion: Sep 2024153 patients
Phase 3Completed
NCT04697056Vanda PharmaceuticalsImsidolimab

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

Start: Jan 2021Est. completion: Nov 20215 patients
Phase 2Terminated
NCT04154293Leo PharmaTMB-001

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

Start: Dec 2019Est. completion: Aug 202134 patients
Phase 2Completed
NCT03417856GaldermaDefining the Skin and Blood Biomarkers of Ichthyosis

Defining the Skin and Blood Biomarkers of Ichthyosis

Start: Jan 2018Est. completion: Dec 2027200 patients
N/AEnrolling By Invitation

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.